
The prevalence of cytomegalovirus infection in a group of pregnant women in Brack Al-Shati, Libya

Somia A. Al-Ghani¹, Salma M. Aljad¹, Omar M. Abukhres², Ibrahim A. Mukhtar³, Ali F. Hawad¹ and Hussein. Al-Rasheed¹

1. Department of medical laboratory technology, faculty of engineering and technology, university of sebha, Libya, 2. Faculty of dentistry, Al-Jabel Al-Gharbi university, Alzentan, Libya, 3. Faculty of medical technology, university of Tripoli, Tripoli, Libya

Abstract: This study was undertaken to examine the prevalence of cytomegalovirus in a group of women in the area of Brack Al-Shati

Serum samples were collected from 180 pregnant women attending Brack general hospital for consultation and treatment. Women chosen for the study were in different gestation weeks. Medical history and relevant information were recorded. Samples were examined serologically by enzyme linked immunosorbent assay (ELISA) to measure the titer of immunoglobulin G (IgG) against cytomegalovirus.

One hundred and seventy two (95.6%) of samples were positive for the cytomegalovirus, with titers range between 1.6-58.17 IU/ml.

Conclusion: CMV is quite common in this area. 20% of CMV positive women suffer from complications such as abortions, defected babies etc., and this probably due to the infection with CMV.

Key words: cytomegalovirus, pregnant, women, infection and gestation.

Introduction

The term cytomegalo means a cell of great size and describes the appearance of cells infected with this herpes virus. Cytomegalovirus (CMV) is a member of the family Herpesviridae. CMV is a public health problem which can be a potential killer or lifelong silent companion (1). Morphologically is very similar to other herpes viruses (1, 2, and 3). The replication of the CMV occurs in the nucleus. Like all herpes viruses, viral DNA integrates with host cell DNA to establish a latent infection. Therefore, CMV infection result from either primary exposure, or a reactivation of latent virus. CMV has been shown to infect a broad spectrum of cells in vivo. For this reason the CMV can be shown in various body organs. However, in the laboratory it is usually grown in human fibroblast cell line (4, 5). Acute infection usually occurs in

immunosuppressed and AIDS patients, and the symptoms vary from mild to severe. The severity of infection depend on a number of factors, such as the age of host, his immune status and the stage of pregnancy at the time of acquiring the infection ("congenital") (6,7). Recently certain antiviral drugs have been used to control the CMV infection and to improve the life expectancy in this group of patients (5, 8). Studies have shown the latency of CMV inside lymphocytes cause several changes in T-lymphocytes differentiation; this will increase the rate of infectious diseases and the rate of death among aged patients (8). The virus can escape certain defense mechanisms by producing certain proteins, these proteins interfere with the major histocompatibility complex class I proteins and prevent their preparation and introduction to cytotoxic T-

lymphocytes and therefore, the CMV infection become difficult to control (5). CMV infection in pregnancy is extremely serious and considered a major health issue in several parts of the world which requires precautionary measures. Congenital infections are acquired when the developing fetus becomes infected by CMV crossing the placental tissues from a mother who acquired a primary CMV infection during the pregnancy. Some of these congenitally infected infants are born with severe deformities and die shortly after birth (10). CMV is among the leading congenital causative agents in developed countries (9). Furthermore, the immunity of the mother does not provide protection against congenital infection but it reduces the severity of symptoms during acute infection (10). Table 1 shows the effects of primary and latent infection on pregnant women and their fetuses.

Severe symptoms also seen on unborn fetus and neonatal, but the problem of CMV infections in pregnancy is perceived by scientific community and public health authorities. Consequences of CMV in pregnancy had seen as congenital CMV after primary or recurrent maternal infection. primary infection has occur at 1-4 % for pregnant mother who are 45% of pregnant woman in higher income group and 15% of pregnant women in lower income group, where 40% of them transmit infection to their fetus clinic features just had seen in 10-15% outstanding recurrent maternal infection was 0.15% in the higher income group of pregnant women who were 55% immune. The overall incidence of congenital HCMV varies from 0.24% to 2.2% this percentage includes newborn born to mothers with primary or recurrent infection. There is

some difference between countries, where the incidence increased to 5.4% at Sukuta village in Gambia (7).

The virus have multiple mechanisms of immune evasions for HCMV could be related to pathogenic role of the virus include US2, US3, US6, US11, and US16. There are a number of recent assays to prognostic and diagnosis maternal and fetal infection.

In fact, although existing immunity does not prevent transmission of the virus to the fetus, over the last 30 years attempts to develop any HCMV vaccine that have been directed at the five major strategic approaches: live attenuated recombinant virus subunit, peptide and DNA vaccines this program aimed to develop a safe and effective vaccine that reduce incidence of primary infection at pregnant women. In Libya studies concerned with the prevalence of CMV are rare and therefore, this study was undertaken to examine the prevalence of cytomegalovirus infection in a group of pregnant women attending to Brack general hospital for consultation and treatment.

Materials and Methods:

One hundred and eighty pregnant women who attended Brack general hospital for consultation and treatment during the period between July and October 2008 were taken as a study group. Serum samples have been collected from women at difference gestation weeks, after collecting some information related to patients history were taken, these included age of patient, accommodation , pregnancy period and other medical history information such as abortion , and delivery of newborns with special symptoms such as hepatosplenomegaly, microcephaly, hearing loss , blindness

and mental retardation . Then the women were asked if they were on certain drugs such as Aspirin.

Samples were examined serologically by enzyme linked Immuno – sorbent assay (ELISA) to measure the titer of immunoglobulin G (IgG) against CMV.

Results:

This study was performed on 180 pregnant women aged between 17–43 years, mean = 28.64 years, thirty nine women at the first trimester (22%), thirty six (20%)at the second trimester, and one hundred and five (58 %) at the last trimester of gestation. One hundred and seventy two samples (95.6%) were positive based on the

test criteria (titer more than1.0 unit). With titer ranged between 1.6–58.16U/ml average 21.14 IU. Eight samples) 4.4%) were negative, titer ranged between 0.16-1.05IU/ml average (0.63IU/ml). The prevalence of infection was increased with the age since raised the prevalence from 90.9% at ages between 16 to 20 years to arrive 100% in the age older than 30 years Table 3.1. Furthermore, there is no significant variation in the titer in different gestation groups Table 3.2.

Table 3.1 the Anti-CMV titer among different age groups

Age years	specimens	Positive (%)	Concentration of CMV IgG IU/ml (mean)
16 –20	11	10(90.9%)	6.73-34.68 (18.46)
21–25	56	52(92.9%)	4.51-58.17 (21.12)
26–30	56	53(94.4%)	2.37-42.13 (21.71)
31–35	30	30(100%)	3.25-39.71 (23.17)
36–40	20	20(100%)	3.91-39.72 (18.71)
37–45	7	7(100%)	1.6-33.29 (18.94)
Total	180	172(95.6%)	1.6-58.17 (21.14)

Table 3.2 the variation of anti-CMV titer with gestation stage

Period of gestation trimester	Specimens	Positive (%)	Concentration of CMV IgG IU/ml (mean)
First	39	37 (95%)	2.37-44.54 (22.05)
Second	36	35 (97%)	3.25-39.71 (23.43)
Third	105	100 (95%)	1.6-58.17 (19.99)
Total	180	172 (95%)	1.6 58.17 (21.14)

About thirty women had a medical history of abortion and newborn abnormalities, these congenital abnormalities include microcephaly, hearing loss, hepatosplenomegaly and late hearing loss. According to medical

analysis most women did not have history of rubella infection nor toxoplasmosis. 153 pregnant women didn't take aspirin at gestation.

Discussion

The results of this study have indicated high prevalence of CMV infection in this region of Libya. The results of this study was similar to results of another studies carried out in countries such as Egypt and turkey (9,10) .

But it is higher than recent studies at developed and manmade such as Australia. Italy, Japan, high prevalence of infection at previous countries depends on many factors, including family size, social habits, income, at other side, decrease of infection at developed countries refers to medical assurance, health care, and economic development. results of this study ensure numerous of women at childbearing have specific antibodies against cytomegalovirus that give protection against primary infection of cytomegalovirus, so it decreases risk of infection on fetus in future at the study region, at the same time, high prevalence of community indicate increased Probability of reinfection by new strains or recurrent infection by first strain or other strains at any age.

According to age in this study group the prevalence of CMV infections raised from 92.5% at ages less than 25 yrs to get 97.3% at ages older than 25 years. There is no significance difference of HCMV specific IgG titer , neither at difference gestation stages, nor at having aspirin during gestation . Thirty six pregnant women suffered from abortion problem or delivered babies with different abnormalities , examinations at the time of these problems ensure that they were not suffering from toxoplasmosis nor rubella diseases although they were not examined for CMV at that time we suggest that the CMV could be the reason of these problems as examination for CMV after years of these problems revealed titer of CMV specific IgG ranged between 2.37 to 39.32 IU/ml. commonly a titer of CMV antibodies are mild high at most seropositive pregnant. In conclusion: CMV is quite common in this area. 20% of CMV positive women suffer from complications such as abortions, defected babies etc., and this probably due the infection with CMV.

دراسة انتشار عدوى أحمة المضخمة للخلايا بين مجموعة من النساء الحبلية في منطقة براك الشاطي، ليبيا

سمية أبو بكر الغاني¹, عمر محمد أبوخريص², إبراهيم السنوسي مختار³, علي فرج هواد¹ و حسين أحمد الرشيد⁴

1. قسم المختبرات الطبية، كلية العلوم الهندسية والتقنية، جامعة سبها، براك الشاطي، ليبيا، 2. كلية طب الأسنان جامعة الجبل الغربي، غريان، ليبيا، 3. قسم الصحة العامة، كلية التقنية الطبية، جامعة طرابلس، طرابلس، ليبيا، 4. كلية الطب جامعة سبها
* جميع المراسلات: عمر محمد أبوخريص، كلية طب الأسنان جامعة الجبل الغربي، غريان، ليبيا
omarabukhres@yahoo.com البريد الإلكتروني:

ملخص: أجريت هذه الدراسة لتقييم مدى انتشار أحمة المضخمة للخلايا في مجموعة من النساء الحبلية في منطقة براك الشاطي. أخذت عينات دم من مائة وثمانين سيدة يترد دانا علي مستشفى براك العام للعلاج والاستشارة. السيدات اللواتي تم اختيارهن للدراسة كُنَّ في أسابيع مختلفة من الحمل. تم تسجيل التاريخ الطبي والمعلومات ذات العلاقة. العينات تم فحصها مصليا باستخدام اختبار الامتصاص المناعي الأنزيمي (ELISA) لقياس عيار الكريينات المناعية G(IgG) مقابل أحمة المضخمة للخلايا. عدد مائة واثنان وسبعين سيدة بنسبة (95.6%) من العينات كانت إيجابية للحمة المضخمة للخلايا، بمدى عياري بين 1.6-58.17 IU / مليلتر. خلصت هذه الدراسة ألي إن أحمة المضخمة للخلايا شائعة بين النساء في منطقة الدراسة، 20 % من النساء الإيجابيات للحمة المضخمة للخلايا يعانين من بعض المضاعفات مثل الإجهاض وإنجاب أطفال مشوهين ومضاعفات أخرى. ويحتمل أن تكون هذه المضاعفات نتيجة الإصابة بأحمة المضخمة للخلايا.
الكلمات الاستدلالية: أحمة المضخمة للخلايا، نساء، عدوى و الحمل.

. References :

- 1- Revello MG. and Gerna G. (2002). Diagnosis management of human cytomegalovirus infection in mother, fetus and newborn infant. clinical microbiology reviews , 15(5) 680-715
- 2- Robbins SL. and Kumar V. (1987). basic pathology. 4 ed . saunders USA .
- 3- Levinson W. (2006). Review of medical microbiology 9 ed. The McGraw-Hill Companies. USA.
- 4- Harvey RA., Champe RC.and Fisher BD. (2007). Microbiology lippincott's illustrated reviews .2 ed. Lippincott Williams and wilkins .USA.
- 5- Sokal EM ., Veyekemans F., Goyet J., Moulin D., Hoorebeek NV., Alberti D., Bust JP., Rahier J., obbergh LV., clapuyt P., carlier P ., carlier M ., claus D ., latinne D ., hemptinne B .and Botte J. (1990) . Liver transplantation in children less than 1 year of age. The journal of pediatrics; 117(2): 207-219.
- 6- Sprctor SA., Hisa K., Crager M., pilcher Mcabral S ., Stempien MJ. (1999). Cytomegalovirus CMV DNA load is an Independent predictor of CMV disease and survival in

- advanced AIDS. journal of virology; 73(8): 7027-7030.
- 7- Van der sande MAB., Kaye S., Miles DJC., Waight P., Jeffries DJ., and Ojuola(2007).** Risk factor for clinical outcome of congenital cytomegalovirus infection in A peri-Urban west Africa birth cohort plos one; 2(6): e492.
- 8- Sutherland CL. ,Chalupny NJ. Cosman D. (2001).** The UL-16 binding proteins A novel family of MHC class I related ligands for NKG2D. Activate natural killer cell function. Immunology. 181 185-192.
- 9- El-nawawy A., soliman AT. El-azzouni O. Amer E . karim MA. Demian S. el-sayed M. (1996).** Maternal and neonatal prevalence of toxoplasma and cytomegalovirus antibodies and hepatitis B anting in Egyptian rural area. Journal of tropical pediatrics. 42(3): 154-157.
- 10 - Hirota K., muraquchi K., watabe N., okumure M., kozu M. Tokahashi K., Machida Y., funayama Y., oshima T.and numazaki Y. (1992).** Prospective study on maternal intrauterine and prenatal infection with cytomegalovirus in Japan during 1976-1990 journal of medical virology. 37(4):303-306.